Comparing transrectal vs transperineal biopsies in patients with prostate cancer
“The thought [for transperineal biopsy] is that if you can avoid introducing some rectal bacteria into the tissue, that we may be able to totally avoid or at least minimize the post-biopsy infections,” says Badar M. Mian, MD, FACS.
In this video, Badar M. Mian, MD, FACS, discusses the advantages and disadvantages of 2 types of approaches to prostate biopsy: transrectal biopsy, the current standard of care, and the newer transperineal technique. Mian is a professor of surgery and urology at Albany Med Urology in Albany, New York.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
